Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Aridis Pharmaceuticals Inc (ARDS)

OTC Markets
Currency in USD
Disclaimer
0.010
0.000(0.00%)
Closed

ARDS Income Statement

Advanced Income Statement
Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa11.543.09
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-2.15%+53.5%+101.37%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa16.9636.9425.7
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-15.96-35.4-22.61
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+30.81%-121.87%+36.15%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-1,595.6%-2,306.25%-731.32%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa6.457.317.16
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-22.4-42.71-29.77
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+22.99%-90.67%+30.31%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-2,240.1%-2,782.48%-962.99%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa0.08-0.25-0.12
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-78.43%-418.18%+50.61%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa--0.25-0.12
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa0.08--
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-0.010.070.09
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-22.33-42.88-29.79
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa---
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-0.69-0.58
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-22.33-42.19-30.37
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+24.76%-88.93%+28.02%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa-2,233.3%-2,748.73%-982.56%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa---
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-22.33-42.19-30.37
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa---
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-22.33-42.19-30.37
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+24.76%-88.93%+28.02%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-2,233.3%-2,748.73%-982.56%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-4.13-
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-22.33-46.32-30.37
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-2.44-3.77-1.62
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+30.59%-54.71%+57.08%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-2.44-3.77-1.62
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+30.59%-54.71%+57.08%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa9.1712.2918.78
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa9.1712.2918.78
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa---
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa---
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-22.06-42.28-29.28
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+23.25%-91.61%+30.74%
EBITDA Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-2,206.4%-2,754.14%-947.23%
EBIT
aa.aaaa.aaaa.aaaa.aaaa.aa